JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

Inclusion Criteria:

* Histologically (or cytologically) confirmed, unresectable metastatic colorectal cancer.
* KRAS G12C mutation.
* At least one measurable disease per RECIST v1.1; assessed within 28 days before first dose.
* Subject have withdrawn from the first-line chemotherapy due to disease progression or unacceptable toxicity; if first-line chemotherapy and maintenance therapy were received, disease progression must within three months; first-line chemotherapy regimens do not limit the use of antiangiogenic agents.
* Adequate bone marrow, liver and renal function.
* ECOG performance status 0-1.
* Informed consent has been signed.

Exclusion Criteria:

* Patients have received KRAS G12C inhibitors.
* Patients have received a first-line treatment, which include fluoropyrimidine, oxaliplatin and irinotecan.
* Patients who are pregnant or breastfeeding.
* Life expectancy of less than 3 months.
* Patients who had major surgery or significant trauma within 4 weeks prior to the first blood sample collection during the screening period, or expected to require major surgery during the study period.
* Patients with active ulcers and gastrointestinal bleeding.
* Prior history of interstitial lung disease or non-infectious pneumonia; history of active tuberculosis.
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
* Patients with clinically diagnosed autoimmune disease; HIV, HCV positive; HBV-DNA beyond the normal range of the laboratory; Acute CMV infection.
* Patients with active central nervous system metastases requiring treatment.
* Patients with other malignancies within five years.
* Assessed by the investigator, patients who are unable or unwilling to comply with the requirements of the study protocol.